La UEG Week se ha celebrado en Copenhague del 14 al 17 de octubre. A continuación puede consultar la producción de los miembros de GETECCU en la reunión:

Comunicaciones GETECCU en la UEGW 2023

Comunicaciones orales

OP107: IS THE WITHDRAWAL OF ANTI-TUMOUR NECROSIS FACTOR IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION FEASIBLE WITHOUT INCREASING THE RISK OF RELAPSE? RESULTS FROM THE RANDOMISED CLINICAL TRIAL OF GETECCU (EXIT) María Chaparro

OP168 HIV INFECTION IS ASSOCIATED WITH A LESS AGGRESSIVE PHENOTYPE OF INFLAMMATORY BOWEL DISEASE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY Margalida Calafat Sard

Póster

MP200 PREVALENCE OF UNDIAGNOSED INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHRITIS: EISER STUDY. Ana Gutiérrez Casbas

PP0566 CHARACTERISTICS AND MANAGEMENT OF PYODERMA GANGRENOSUM AND ERYTHEMA NODOSUM IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: PIONOSO MULTICENTER STUDY Iago Rodríguez-Lago

PP0666 USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY Margalida Calafat Sard

PP0825 ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY Jordina Llaó

PP0884 REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY Alejandro Garrido

Póster moderado

MP200 PREVALENCE OF UNDIAGNOSED INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHRITIS: EISER STUDY Ana Gutiérez Casbas